BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31264438)

  • 1. Implementation and Outcomes of a Molecular Tumor Board at Herbert-Herman Cancer Center, Sparrow Hospital.
    Trivedi H; Acharya D; Chamarthy U; Meunier J; Ali-Ahmad H; Hamdan M; Herman J; Srkalovic G
    Acta Med Acad; 2019 Apr; 48(1):105-115. PubMed ID: 31264438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical pharmacy pilot within a Precision Medicine Program for cancer patients and review of related pharmacist clinical practice.
    Arnall JR; Petro R; Patel JN; Kennedy L
    J Oncol Pharm Pract; 2019 Jan; 25(1):179-186. PubMed ID: 29078708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
    Tafe LJ; Gorlov IP; de Abreu FB; Lefferts JA; Liu X; Pettus JR; Marotti JD; Bloch KJ; Memoli VA; Suriawinata AA; Dragnev KH; Fadul CE; Schwartz GN; Morgan CR; Holderness BM; Peterson JD; Tsongalis GJ; Miller TW; Chamberlin MD
    Oncologist; 2015 Sep; 20(9):1011-8. PubMed ID: 26205736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Medicine in Oncology Pharmacy Practice.
    Saadeh C; Bright D; Rustem D
    Acta Med Acad; 2019 Apr; 48(1):90-104. PubMed ID: 31264437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers.
    Rodriguez-Rodriguez L; Hirshfield KM; Rojas V; DiPaola RS; Gibbon D; Hellmann M; Isani S; Leiser A; Riedlinger GM; Wagreich A; Ali SM; Elvin JA; Miller VA; Ganesan S
    Gynecol Oncol; 2016 Apr; 141(1):2-9. PubMed ID: 27016222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
    Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
    Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision medicine in oncology: New practice models and roles for oncology pharmacists.
    Walko C; Kiel PJ; Kolesar J
    Am J Health Syst Pharm; 2016 Dec; 73(23):1935-1942. PubMed ID: 27864201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons learned: the first consecutive 1000 patients of the CCCMunich
    Heinrich K; Miller-Phillips L; Ziemann F; Hasselmann K; Rühlmann K; Flach M; Biro D; von Bergwelt-Baildon M; Holch J; Herold T; von Baumgarten L; Greif PA; Jeremias I; Wuerstlein R; Casuscelli J; Spitzweg C; Seidensticker M; Renz B; Corradini S; Baumeister P; Goni E; Tufman A; Jung A; Kumbrink J; Kirchner T; Klauschen F; Metzeler KH; Heinemann V; Westphalen CB
    J Cancer Res Clin Oncol; 2023 May; 149(5):1905-1915. PubMed ID: 35796778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
    Bryce AH; Egan JB; Borad MJ; Stewart AK; Nowakowski GS; Chanan-Khan A; Patnaik MM; Ansell SM; Banck MS; Robinson SI; Mansfield AS; Klee EW; Oliver GR; McCormick JB; Huneke NE; Tagtow CM; Jenkins RB; Rumilla KM; Kerr SE; Kocher JA; Beck SA; Fernandez-Zapico ME; Farrugia G; Lazaridis KN; McWilliams RR
    Oncotarget; 2017 Apr; 8(16):27145-27154. PubMed ID: 28423702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physician interpretation of genomic test results and treatment selection.
    Brusco LL; Wathoo C; Mills Shaw KR; Holla VR; Bailey AM; Johnson AM; Khotskaya YB; Litzenburger BC; Sanchez NS; Zeng J; Bernstam EV; Eng C; Kee BK; Amaria RN; Routbort MJ; Mills GB; Mendelsohn J; Meric-Bernstam F
    Cancer; 2018 Mar; 124(5):966-972. PubMed ID: 29165790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implementation and utilization of the molecular tumor board to guide precision medicine.
    Harada S; Arend R; Dai Q; Levesque JA; Winokur TS; Guo R; Heslin MJ; Nabell L; Nabors LB; Limdi NA; Roth KA; Partridge EE; Siegal GP; Yang ES
    Oncotarget; 2017 Aug; 8(34):57845-57854. PubMed ID: 28915716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations.
    Koopman B; Groen HJM; Ligtenberg MJL; Grünberg K; Monkhorst K; de Langen AJ; Boelens MC; Paats MS; von der Thüsen JH; Dinjens WNM; Solleveld N; van Wezel T; Gelderblom H; Hendriks LE; Speel EM; Theunissen TE; Kroeze LI; Mehra N; Piet B; van der Wekken AJ; Ter Elst A; Timens W; Willems SM; Meijers RWJ; de Leng WWJ; van Lindert ASR; Radonic T; Hashemi SMS; Heideman DAM; Schuuring E; van Kempen LC
    Oncologist; 2021 Aug; 26(8):e1347-e1358. PubMed ID: 33111480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronological improvement in precision oncology implementation in Japan.
    Sunami K; Naito Y; Komine K; Amano T; Ennishi D; Imai M; Kage H; Kanai M; Kenmotsu H; Koyama T; Maeda T; Morita S; Sakai D; Kohsaka S; Tsuchihara K; Saigusa Y; Yoshino T
    Cancer Sci; 2022 Nov; 113(11):3995-4000. PubMed ID: 35976133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study.
    Perez JK; Kleber J; Rothe M; Mangat P; Garrett-Mayer E; Schilsky RL
    JCO Precis Oncol; 2024 Mar; 8():e2300615. PubMed ID: 38564684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
    Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
    Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmatic Precision Oncology Decision Support for Patients With Gastrointestinal Cancer.
    Keller RB; Mazor T; Sholl L; Aguirre AJ; Singh H; Sethi N; Bass A; Nagaraja AK; Brais LK; Hill E; Hennessey C; Cusick M; Del Vecchio Fitz C; Zwiesler Z; Siegel E; Ovalle A; Trukhanov P; Hansel J; Shapiro GI; Abrams TA; Biller LH; Chan JA; Cleary JM; Corsello SM; Enzinger AC; Enzinger PC; Mayer RJ; McCleary NJ; Meyerhardt JA; Ng K; Patel AK; Perez KJ; Rahma OE; Rubinson DA; Wisch JS; Yurgelun MB; Hassett MJ; MacConaill L; Schrag D; Cerami E; Wolpin BM; Nowak JA; Giannakis M
    JCO Precis Oncol; 2023 Jan; 7():e2200342. PubMed ID: 36634297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implementation of a molecular tumor board at a regional level to improve access to targeted therapy.
    Bourien H; Lespagnol A; Campillo-Gimenez B; Felten-Vinot I; Metges JP; Corre R; Lesimple T; le Marechal C; Boussemart L; Kammerer-Jacquet SF; le Gall E; Denoual F; de Tayrac M; Galibert MD; Mosser J; Edeline J
    Int J Clin Oncol; 2020 Jul; 25(7):1234-1241. PubMed ID: 32215806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
    Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
    Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience.
    Repetto M; Crimini E; Boscolo Bielo L; Guerini-Rocco E; Ascione L; Bonfanti A; Zanzottera C; Mazzarella L; Ranghiero A; Belli C; Criscitiello C; Esposito A; Barberis MCP; Curigliano G
    Eur J Cancer; 2023 Apr; 183():79-89. PubMed ID: 36801623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.